pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CRISPR/Cas9 · news · pharmadog
← back to CRISPR/Cas9
News · CRISPR/Cas9
180
stories
2d
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
3d
Ramping up: 3 biotechs growing their workforce after series C raises
biospace
4d
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
fiercebiotech
5d
Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
biospace
5d
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
biospace
5d
Marrow raises $173M for siRNA drug competing with CRISPR therapy for sickle cell
endpoints
5d
Marrow sets out to challenge genetic medicines for severe blood diseases
biopharma dive
6d
Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
biospace
6d
Big-name investors pour $100M into DNA therapeutics developer Seawolf
biopharma dive
6d
Chinese scientists fired after child dies in gene editing study: report
fiercebiotech
8d
Cellectis could cut 70% of workforce in shift to in vivo therapies
biospace
9d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
9d
This week in charts: Brain drugs are back on venture capitalists’ minds
biopharma dive
9d
Marrow extracts $120M series B to advance preclinical blood disease therapy
fiercebiotech
9d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
9d
Webinar: Optimizing Cell Therapy Manufacturing Efficiency with Cryopreserved Cells
biospace
9d
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
fiercebiotech
11d
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
biopharma dive
12d
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
biospace
12d
STAT+: GLP-1s are given an FDA warning for rare eye condition risk
stat
12d
Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
fiercebiotech
16d
STAT+: A possible comeback for a failed sickle cell gene therapy
stat
17d
Single-payer health care system proponents were thrown a big bone this election
stat
17d
#ASH26: Kamau shares first data from revamped sickle cell gene editing therapy
endpoints
18d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
19d
UniQure gets an FDA decision date; Teva scraps brain drug study
biopharma dive
20d
Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push
biospace
20d
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
biospace
24d
FDA charts path for approval of individualized gene editing therapies
endpoints
25d
FDA unveils guidance for ‘plug and play’ gene therapies
biopharma dive
← prev
page 1 of 6
next →